Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC5963 | [Nle4,D-Phe7]-α-MSH |
| Synthetic analog of α-MSH that is an agonist at melanocortin receptors (Ki values are 0.085, 0.4, 3.8 and 5.1 nM for MC1, MC3, MC4 and MC5 receptors respectively). | |
| BCC5964 | HOE 140 |
| Potent and selective bradykinin B2 receptor antagonist (pA2 = 9.04). Also inhibits aminopeptidase N (Ki = 9.1 μM). | |
| BCC5971 | HU 308 |
| Potent and selective CB2 receptor agonist (Ki values are 22.7 nM and > 10 μM for CB2 and CB1 receptors respectively, EC50 = 5.57 nM). Displays antiallodynic activity in the rat hindpaw incision model of postoperative pain. Also neuroprotective and improves motor performance in a mouse model of Huntington's Disease. | |
| BCC5972 | PHA 543613 hydrochloride |
| Potent α7 nAChR agonist that displays selectivity over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors. Positively influences sensory gating and memory in in vivo models of schizophrenia. Orally active and brain penetrant. | |
| BCC5974 | α-Conotoxin ImI |
| Nicotinic receptor antagonist that displays selectivity for homomeric α7 and α9 receptors (IC50 values are 220 and 1800 nM respectively). Displays no effect on α2β2, α3β2, α4β2, α2β4, α3β3 and α4β4 subunit combinations. | |
| BCC5975 | α-Conotoxin AuIB |
| Selective antagonist of α3β4 nicotinic acetylcholine receptors. Displays > 100-fold selectivity over other receptor subunit combinations including α2β2, α2β4, α3β2, α4β2, α4β4 and α1β1γδ. | |
| BCC5976 | α-Conotoxin PIA |
| Selective antagonist of α6-containing nicotinic receptors that discriminates between the closely related α6 and α3 subunits (IC50 values are 0.95 and 74.2 nM for rat α6/α3β2β3 and α3β2 receptors respectively). | |
| BCC5977 | Conantokin-T |
| Non-competitive NMDA receptor antagonist (IC50 = 0.4 μM). Inhibits Ca2+ influx and glutamate-induced toxicity in central nervous system neurons. Exhibits age-dependent physiological effects; induces a sleep-like state in young mice and hyperactivity in older mice. | |
